Sorafenib-encapsulating micelles coated with ApoE peptides enhanced anti-GBM activity 10.6- and 12.9-fold, and GBM accumulation 6.0- and 2.5-fold, compared to free sorafenib and non-targeted micelles, respectively [364]. This evidence concerns the gene APOE and glioblastoma.